Adding Pembrolizumab to Chemotherapy Results in Improved PFS and OS in Patients with Advanced and Recurrent Cervical Cancer Regardless of Bevacizumab Use By Ogkologos - November 25, 2024 892 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the subgroup analysis of the KEYNOTE-826 study Source RELATED ARTICLESMORE FROM AUTHOR FDA Approves Belzutifan with Pembrolizumab for Adjuvant Treatment of Renal Cell Carcinoma How Decades of NCI Support Led to Groundbreaking Discoveries: The Story of Immune Checkpoint Inhibitors Adding Belzutifan to Pembrolizumab Prolongs DFS After Nephrectomy in Patients with ccRCC at Increased Risk for Recurrence MOST POPULAR New on NCI’s Websites for August 2024 August 16, 2024 FDA Approves Enzalutamide for Non-Metastatic Castration-Sensitive Prostate Cancer with Biochemical Recurrence December 15, 2023 How repurposing a drug in a COVID-19 trial could benefit people... March 2, 2021 FDA Approves Inavolisib with Palbociclib and Fulvestrant for Endocrine-Resistant, PIK3CA-mutated, HR-positive,... November 20, 2024 Load more HOT NEWS Speaking a thousand words – how a cancer image collection is... Miss New Jersey Collegiate USA Uses Her Prestigious Position to Shed... Chemo before surgery helps stop colon cancer coming back EMA Recommends Granting a Marketing Authorisation for Lisocabtagene Maraleucel
